EURopean trial On reduction of cardiac events with Perinopril in stable coronary Artery disease (EUROPA) trial

Introduction

Study design:

• 12,218 patients with:
  • stable coronary artery disease (CAD)
  • no heart failure
• perindopril target dose 8 mg QD vs. placebo
• standard CAD therapy
• mean follow-up of 4.2 years
• randomized study supported by manufacturer of perindopril

Results:

• rate of cardiovascular death, nonfatal myocardial infarction or cardiac arrest with successful rescuscitation was significantly lower in perindopril group than placebo group (8% vs 10%)
• benefit evident even among patients taking:
  • beta-blocker
  • hypolipidemic agent
  • calcium channel blocker
• benefit evident in diabetic patients
• perindopril lowered blood pressure by an average of:
  • 5 mm Hg systolic
  • 2 mm Hg diastolic
• improved outcomes noted in patients with or without hypertension

More general terms

• clinical trial

Additional terms

• PEACE study